New guidelines have lowered the recommended starting age for colorectal cancer screening. One expert says clinicians need to do more to increase screening access and compliance while ensuring no patient population is left behind.
Recent trials and studies have led to promising insights and new options for the management and treatment of GERD for some patients.
Key milestones have shaped our knowledge of the gut microbiota and its role in human health.
A retrospective analysis shows that steroid-sparing therapy helps prevent perianal fistulizing complications by nearly 60%.
Endoscopic submucosal dissection was shown to be highly effective at removing superficial gastric tumors and is a viable option for patients around the globe.
In 2015, 1.3% of U.S. adults — around 3 million people — had diagnosed inflammatory bowel disease (IBD) such as Crohn’s disease or ulcerative colitis.
Current antibiotic treatments for Clostridioides difficile infection (CDI), which causes the chronic, degenerative disease colitis, eliminate beneficial bacteria in the gut along with the harmful pathogen. Researchers at North Carolina State University (NCSU) have taken the first step toward developing a therapy that attacks C. difficile while sparing other microbes.
Alzheimer’s disease, irritable bowel disease and osteoarthritis place a heavy burden on patients, caregivers and the healthcare system.
Telephone- and web-based cognitive behavioral therapy (CBT) show promise as effective long-term treatments for irritable bowel syndrome (IBS) symptoms, according to a recent study.
Observational studies have linked proton pump inhibitors (PPIs) to a litany of health conditions. A recent randomized controlled trial undermines many of those associations, finding PPIs to be largely safe to use for at least three years.
- 1 of 4
- next ›